BridgeBio: Strong Start For Attruby

Group 1 - BridgeBio's shares (NASDAQ: BBIO) are approaching 52-week highs following strong fourth quarter results and a positive commercial update on Attruby, which has seen over 1,000 unique patient prescriptions in the United States [2] - The Growth Stock Forum focuses on identifying attractive risk/reward situations in growth stocks, particularly in the biotech sector, and maintains a model portfolio of 15-20 stocks that is updated regularly [2] Group 2 - The article reflects the author's personal opinions and does not constitute investment advice or recommendations for buying or selling stocks [3][4]